Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short term Debt (2017 - 2026)

Ani Pharmaceuticals' Short term Debt history spans 10 years, with the latest figure at $17.3 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 88.27% to $17.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.3 million, a 88.27% increase, with the full-year FY2025 number at $17.3 million, up 88.27% from a year prior.
  • Short term Debt hit $17.3 million in Q4 2025 for Ani Pharmaceuticals, up from $15.2 million in the prior quarter.
  • Over the last five years, Short term Debt for ANIP hit a ceiling of $25.0 million in Q2 2023 and a floor of $229000.0 in Q1 2025.
  • Historically, Short term Debt has averaged $7.1 million across 5 years, with a median of $850000.0 in 2021.
  • Biggest five-year swings in Short term Debt: soared 2844.12% in 2023 and later plummeted 96.64% in 2024.
  • Tracing ANIP's Short term Debt over 5 years: stood at $850000.0 in 2021, then changed by 0.0% to $850000.0 in 2022, then changed by 0.0% to $850000.0 in 2023, then surged by 979.06% to $9.2 million in 2024, then soared by 88.27% to $17.3 million in 2025.
  • Business Quant data shows Short term Debt for ANIP at $17.3 million in Q4 2025, $15.2 million in Q3 2025, and $13.2 million in Q2 2025.